Article

Interstitial transfer factor as adjuvant immunotherapy for experimental glioma.

Neuroimmunology Unit, National Institute of Neurology and Neurosurgery of Mexico, Mexico City.
Journal of experimental & clinical cancer research: CR (Impact Factor: 3.27). 12/2005; 24(4):575-83.
Source: PubMed

ABSTRACT Glioblastoma multiform (GBM) is the most common tumour of the central nervous system in humans. Unfortunately its prognosis is poor and because of the lack of efficacious therapies, immunotherapy is a potential treatment. Transfer factors (TF) are low molecular weight dialysable products extracted from immune cells which transmit the ability to express delayed-type hypersensitivity and cell mediated immunity from sensitized donors to nonimmnune recipients. In this study, we determined the efficacy of TF as immunotherapy to treat experimental glioblastoma. We used TF obtained from immunized swine. We evaluated different doses of intratumoral TF (product of 4x10(6), 8x10(5) and 1.6x10(5) cells). The best dose (product of 4x10(6) cells) of TF was also combined with carmustine for experimental therapy in rats with C6 malignant glioma. Modifications in peripheral blood T lymphocyte counts ( CD2+, CD4+, CD8+ and NK) were evaluated by flow cytometry. Cytokine expression in the tumour was assessed by RT-PCR and apoptosis was evaluated using the sub G0 method. Intratumoral TF reduced significantly the tumour size, and increased CD2+, CD4+, CD8+ and NK cell counts, it also increased the percentage of apoptotic tumour cells and the percentage of tumour tissue expressing Th1 cytokines. We observed an additive antitumoral effect when TF was combined with chemotherapy.

0 Bookmarks
 · 
108 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Insulin resistance and risk of type 2 diabetes are the most important complications following exposure to organophosphorous (OPs) pesticides. Regarding the importance of liver on metabolic pathways regulation, in particular blood glucose homeostasis, we focused on liver inflammation and oxidative damages in a subchronic model of toxicity by malathion. Adult male Wistar rats of body weight 200-250g were used for the study. Malathion (200mg/kg b.w./day) was administered to rats by oral intubation for 28 days. Glycemic and insulin resistance indices, markers of liver injury, markers of inflammation and oxidative stress were assessed. Malathion-treated rats showed increased glycemia, insulinemia and glycated hemoglobin level, HOMA-IR and HOMA-β indices, plasma activities of hepatocellular enzymes, lipid peroxidation index, CD3(+)/CD4(+) and CD3(+)/CD4(+) and pro-inflammatory cytokines when decreased antioxidant status in liver was noted. Most of our study indicates that malathion promotes insulin resistance, inflammation and Hepatosteatosis in subchronic model of exposure. On the basis of biochemical and molecular findings, it is concluded that insulin resistance induced by malathion occurs through oxidative stress and related pro-inflammatory markers in a way to result in a reduced function of insulin in liver cells.
    Environmental Toxicology and Pharmacology 08/2014; 38(2):542-553. · 1.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Angiotensin II (ANG II) has been associated with vascular proliferation in tumor and non-tumor models through its receptors AT1 and AT2. Our objective was to determine AT1 and AT2 receptor expression in operable breast cancer and its association with tumor grade, vascular density, and cellular proliferation. Methods: Seventy-seven surgically malignant breast tumors with no distant metastasis were included and 7 benign lesions were used as controls. AT1 and AT2 receptor expression was determined by RT-PCR and immunohistochemistry (IHC) in 68 out of the 77 malignant lesions and in the 7 benign lesions. Results: AT1 and AT2 receptor expression was detected in 35.3% and 25% of cases, both by RT-PCR and IHC. Tumors that expressed AT1 receptor showed an increase in T3 stage (92.3% vs 7.7% p<0.001), mitotic index (4 ± 1 vs. 2 ± 1, p= 0.05), vascular density (15  3 vs. 8  5, p = 0.05) and cellular proliferation (85  18 vs. 55  10, p = 0.01) versus AT1-negative lesions. No differences between clinical-pathologic variables and AT2 expression were found. Conclusions: AT1 receptor expression was associated with enhanced angiogenesis and cellular proliferation rate, but no relationship with AT2 receptor was found. ANGII and its peptides may have a role in the development and pathophysiology of breast cancer and could be valuable in the development of targeted therapies. Keywords: ATI, ATII, Angiotensin II, Breast Cancer, Angiogenesis, AT1 blockers.
    Tumor Biology 02/2015; · 2.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To explore the methods for preparing transfer factor specific to Staphylococcus aureus (SA-STF) in vitro.Methods Under the optimum conditions, the spleen cells of rabbits were immunized with SA in vitro to prepare SA-STF, and the immune activities were identified with phagocytosis & sterilization, skin delayed-type hypersensitivity and immune protection tests.ResultsThe concentration of polypeptide was 2.26±0.27 mg/ml and ribose was 0.684±0.094 mg/ml. The phagocytosis and sterilization rates of the STF group was (70.9±12.4)% and (62.1±12.2)% respectively, and comparing with the normal transfer factor (NTF) group, there were no significant differences (P = 0.074 and P = 0.069 respectively). The skin was inflamed and marked nodules formed at the injection site in the mice of the STF group rather than the NTF and control groups. The survival rate of the STF-1 group was significantly higher than those of the STF-2 (P = 0.024) and NTF groups (P = 0.016).ConclusionSA-STF was prepared and characterized successfully in vitro, and it probably is a candidate biological for therapy or adjuvant therapy for disease of Staphylococcus aureus.This article is protected by copyright. All rights reserved
    Biotechnology and Applied Biochemistry 05/2014; · 1.35 Impact Factor